By targeting the IL-4 beta receptor and IL-13, the researchers said, dupilumab (Dupixent; Sanofi, Regeneron) manages atopic dermatitis and improves depression and anxiety, but evidence about its ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Learn about different types of eczema, symptoms, treatment options, and how to differentiate from other skin conditions.

The redness, discoloration, dryness, and itch of atopic dermatitis (AD) could send you to your dermatologist in search of solutions. Your doctor will start by taking stock of your symptoms.

Apogee plans a 2025 Phase 1b trial comparing APG279 to Dupixent in atopic dermatitis. Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who ...

Bubble baths might be soothing soaks, but bubble showers could be the next thing in keeping the skin clean. An Osaka ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal ...

The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic dermatitis ... versus Sanofi and Regeneron’s Dupixent remain unanswered.

Dupixent Market Report 2025 The Business Research Company's Global Dupixent Market Outlook 2025-2034: Growth Drivers, Share, And Trends ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...